...
首页> 外文期刊>BMC Cancer >Association of differential miRNA expression with hepatic vs. peritoneal metastatic spread in colorectal cancer
【24h】

Association of differential miRNA expression with hepatic vs. peritoneal metastatic spread in colorectal cancer

机译:差异miRNA表达与大肠癌肝转移与腹膜转移扩散的关系

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Though peritoneal carcinomatosis reflects a late stage of colorectal cancer (CRC), only few patients present with synchronous or metachronous liver metastases alongside their peritoneal carcinomatosis. It is hypothesized that this phenomenon may be causally linked to molecular characteristics of the primary CRC. This study used miRNA profiling of primary CRC tissue either metastasized to the liver, to the peritoneum or not metastasized at all thus to identify miRNAs potentially associated with defining the site of metastatic spread in CRC. Tissue of the primary tumor stemming from CRC patients diagnosed for either liver metastasis (LM; n?=?10) or peritoneal carcinomatosis (PER; n?=?10) was analyzed in this study. Advanced CRC cases without metastasis (M0; n?=?3) were also included thus to select on those miRNAs most potentially associated with determining metastatic spread in general. miRNA profiling of 754 different miRNAs was performed in each group. MiRNAs being either differentially expressed comparing PER and LM or even triple differentially expressed (PER vs. LM vs. M0) were identified. Differentially expressed miRNAs were further validated by in silico and functional analysis. Comparative analysis identified 41 miRNAs to be differentially expressed comparing primary tumors metastasized to the liver as opposed to those spread to the peritoneum. A set of 31 miRNAs was significantly induced in primary tumors that spread to the peritoneum (PER), while the remaining 10 miRNAs were found to be repressed. Out of these 41 miRNAs a number of 25 miRNAs was triple-differentially expressed (i.e. differentially expressed comparing LM vs. PER vs. M0). The latter underwent in silico analysis. Finally, we demonstrated that miR-31 down-regulated c-MET in DLD-1 colon cancer cells. This study demonstrates that CRC primary tumors spread to the peritoneum vs. metastasized to the liver display significantly different miRNA profiles. Larger patient cohorts will be needed to validate whether determination of e.g. miR-31 may aid to predict the course of disease and whether this may help to create individualized follow up or treatment protocols. To determine whether certain miRNAs may be involved in regulating the metastatic potential of CRC, functional studies will be essential.
机译:尽管腹膜癌病反映了大肠癌的晚期,但只有极少数患者伴随腹膜癌病同时或同时发生肝转移。据推测,这种现象可能与原发性CRC的分子特征有因果关系。这项研究使用了转移到肝脏,腹膜或根本没有转移的原发性CRC组织的miRNA谱图,从而鉴定了可能与确定CRC转移扩散部位有关的miRNA。在本研究中,对来自被诊断为肝转移(LM; n?=?10)或腹膜癌变(PER; n?=?10)的CRC患者的原发肿瘤组织进行了分析。还包括未发生转移的晚期CRC病例(M0; n?=?3),因此可以选择那些通常与确定转移扩散最可能相关的miRNA。在每组中对754种不同的miRNA进行miRNA分析。鉴定出与PER和LM相比差异表达的MiRNA,或者甚至三倍差异表达的PER(LM与LM与M0)。通过计算机和功能分析进一步验证了差异表达的miRNA。对比分析确定了41种miRNA,与转移至肝的原发性肿瘤和扩散至腹膜的原发性肿瘤相比,差异表达。在扩散到腹膜(PER)的原发性肿瘤中,一组31种miRNA被显着诱​​导,而其余10种miRNA被抑制。在这41个miRNA中,有25个miRNA是三差异表达的(即,比较LM,PER和M0的差异表达)。后者进行了计算机分析。最后,我们证明了miR-31在DLD-1结肠癌细胞中下调了c-MET。这项研究表明,CRC原发性肿瘤扩散至腹膜与转移至肝脏之间显示出显着不同的miRNA特性。需要更大的患者队列来验证是否确定miR-31可能有助于预测疾病的进程,以及是否有助于建立个性化的随访或治疗方案。为了确定某些miRNA是否可能参与调节CRC的转移潜力,功能研究必不可少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号